JP7682104B2 - 非小細胞肺がんを処置するための方法および組成物 - Google Patents

非小細胞肺がんを処置するための方法および組成物 Download PDF

Info

Publication number
JP7682104B2
JP7682104B2 JP2021568309A JP2021568309A JP7682104B2 JP 7682104 B2 JP7682104 B2 JP 7682104B2 JP 2021568309 A JP2021568309 A JP 2021568309A JP 2021568309 A JP2021568309 A JP 2021568309A JP 7682104 B2 JP7682104 B2 JP 7682104B2
Authority
JP
Japan
Prior art keywords
antibody
cells
pharmaceutical composition
egfr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532402A5 (enExample
JP2022532402A (ja
Inventor
ジョン ブイ． ヘイマク
モニーク ニルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2022532402A publication Critical patent/JP2022532402A/ja
Publication of JP2022532402A5 publication Critical patent/JP2022532402A5/ja
Priority to JP2025030838A priority Critical patent/JP2025084874A/ja
Application granted granted Critical
Publication of JP7682104B2 publication Critical patent/JP7682104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
JP2021568309A 2019-05-15 2020-05-14 非小細胞肺がんを処置するための方法および組成物 Active JP7682104B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025030838A JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848123P 2019-05-15 2019-05-15
US62/848,123 2019-05-15
PCT/US2020/032968 WO2020232292A1 (en) 2019-05-15 2020-05-14 Methods and compositions for treating non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025030838A Division JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2022532402A JP2022532402A (ja) 2022-07-14
JP2022532402A5 JP2022532402A5 (enExample) 2023-05-22
JP7682104B2 true JP7682104B2 (ja) 2025-05-23

Family

ID=73289322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568309A Active JP7682104B2 (ja) 2019-05-15 2020-05-14 非小細胞肺がんを処置するための方法および組成物
JP2025030838A Withdrawn JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025030838A Withdrawn JP2025084874A (ja) 2019-05-15 2025-02-28 非小細胞肺がんを処置するための方法および組成物

Country Status (6)

Country Link
US (1) US20220265847A1 (enExample)
EP (1) EP3969121A4 (enExample)
JP (2) JP7682104B2 (enExample)
KR (1) KR20220009446A (enExample)
CN (1) CN114126719A (enExample)
WO (1) WO2020232292A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114075548B (zh) * 2020-08-13 2023-11-21 广州医科大学附属第二医院 一种靶向axl的car-t细胞及其制备方法和应用
CN117897405A (zh) * 2021-06-30 2024-04-16 得克萨斯大学体系董事会 靶向cd70-阳性癌症的多肽
WO2023102119A1 (en) * 2021-12-01 2023-06-08 The Brigham And Women's Hospital, Inc. Multispecific t cell engager polypeptides in combination with t cells for cancer therapy
WO2023100153A1 (en) * 2021-12-03 2023-06-08 Crispr Therapeutics Ag Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
WO2025180385A1 (en) * 2024-02-27 2025-09-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/cd70 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015200386A1 (en) * 2008-04-11 2015-02-19 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
WO2012135841A2 (en) * 2011-04-01 2012-10-04 Board Of Regents, The University Of Texas System Emt signatures and predictive markers and method of using the same
CN111499684B (zh) * 2012-06-19 2024-10-22 Ambrx公司 抗cd70抗体药物结合物
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
EP3541389A1 (en) * 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
EP3583129B1 (en) * 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
US20200063100A1 (en) * 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oncogene，2018年08月15日，Vol.38, pp.455-468
Oncotarget，2015年04月19日，Vol.6, No.15, pp.13462-13475

Also Published As

Publication number Publication date
WO2020232292A1 (en) 2020-11-19
US20220265847A1 (en) 2022-08-25
CN114126719A (zh) 2022-03-01
JP2025084874A (ja) 2025-06-03
EP3969121A4 (en) 2024-01-03
EP3969121A1 (en) 2022-03-23
KR20220009446A (ko) 2022-01-24
JP2022532402A (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
US12214037B2 (en) Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
TWI902626B (zh) 嵌合抗原及t細胞受體以及使用方法
KR20220032568A (ko) Flt3l-fc 융합 단백질 및 사용 방법
JP2025084874A (ja) 非小細胞肺がんを処置するための方法および組成物
TW202003581A (zh) 對cd3具特異性之抗體及其用途
US20230322894A1 (en) Methods and compositions for treating glioblastoma
US12479923B2 (en) Chimeric antigen receptors and related methods and compositions for the treatment of cancer
US20250230244A1 (en) Methods and compositions comprising b7-h3 binding polypetides
TW202126696A (zh) 抗epha10抗體及其使用方法
JP7844342B2 (ja) Ｈｓｐ７０を標的とするモノクローナル抗体およびその治療的使用
US20250170177A1 (en) Methods and compositions for treating cancer
JP2024536133A (ja) 抗ｈｓｐ７０抗体およびその治療的使用
US20260034229A1 (en) Antibody-targeted enzymatic chemoprotection
JP7820819B2 (ja) がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物
US20250313640A1 (en) INHIBITION OF CSF-1 or CSF-1R FOR THE TREATMENT OF MINIMAL RESIDUAL DISEASE
HK40126667A (en) Chimeric antigen and t cell receptors and methods of use
HK40128442A (en) Chimeric antigen and t cell receptors and methods of use
HK40071848A (en) Flt3l-fc fusion proteins and methods of use
HK40061606B (en) Chimeric antigen receptors and car-t cells and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230512

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250513

R150 Certificate of patent or registration of utility model

Ref document number: 7682104

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150